MB
MPM BioImpact Portfolio holdings
AUM
$577M
This Quarter Return
+4.84%
1 Year Return
+8.33%
3 Year Return
+241.63%
5 Year Return
+127.38%
10 Year Return
–
AUM
$704M
AUM Growth
+$704M
(+5.7%)
Cap. Flow
+$129M
Cap. Flow
% of AUM
18.31%
Top 10 Holdings %
Top 10 Hldgs %
44.68%
Holding
54
New
11
Increased
21
Reduced
11
Closed
7
Top Buys
| 1 |
Zai Lab
ZLAB
|
$21M |
| 2 |
Scholar Rock
SRRK
|
$18M |
| 3 |
PTC Therapeutics
PTCT
|
$15.6M |
| 4 |
Context Therapeutics
CNTX
|
$15.4M |
| 5 |
Replimune Group
REPL
|
$11.5M |
Top Sells
| 1 |
Insmed
INSM
|
$15.6M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
$15.4M |
| 3 |
KalVista Pharmaceuticals
KALV
|
$10.4M |
| 4 |
Viking Therapeutics
VKTX
|
$7.66M |
| 5 |
Intellia Therapeutics
NTLA
|
$5.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
51
Intellia Therapeutics
NTLA
$1.26B
| – | – |
-267,557
| Closed | -$5.5M |
|
52
Regenxbio
RGNX
$498M
| – | – |
-50,000
| Closed | -$525K |
|
53
Solid Biosciences
SLDB
$448M
| – | – |
-11,518
| Closed | -$80.3K |
|
|
54
Viking Therapeutics
VKTX
$3.02B
| – | – |
-120,982
| Closed | -$7.66M |
|